Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Hepatitis Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Hepatitis Other
    Extending PEG-IFN Alfa-2a Therapy in Patients With Chronic HBV Can Lead to HBeAg Seroconversion, HBsAg Clearance: Presented at AASLD - (DGDispatch)
    Patients Previously Treated With Adefovir Can Achieve Complete Viral Suppression When Switched to Entecavir: Presented at AASLD - (DGDispatch)
    Lamivudine, Entecavir Both Improved Prognosis in Hepatitis B-Related Acute-on-Chronic Liver Failure: Presented at AASLD - (DGDispatch)
    Adefovir Plus Lamivudine Is Effective in Patients With Lamivudine-Resistance Chronic Hepatitis B: Presented at AASLD - (DGDispatch)
    Telbivudine Safe and Effective in Suppressing Hepatitis B Over Very Long Term: Presented at AASLD - (DGDispatch)

    News archive

     Recent webcasts/CME - Hepatitis Other
      HBV-HIV Co-infection
      HBV in Pregnancy
      Debate: Monotherapy vs. Multiple Drug Therapy as the Wave of the Future for HBV Infection
      Hepatitis B Treatment: Current Best Practices How to Avoid Resistance
      Understanding Cultural Barriers

      Webcasts/CME archive

       Recent cases - Hepatitis Other
        A Familial Case of Autoimmune Hepatitis
        A 35-Year-Old Asian Man with Jaundice and Markedly High Aminotransferase Levels
        Acute Hepatitis A Virus Infection Presenting with Multiorgan Dysfunction: A Case Report
        Ceftriaxone-Induced Toxic Hepatitis
        Patient with Hepatitis B and Rheumatoid Arthritis

        Cases archive
          




        my personal edition > hepatitis other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Tenofovir More Effective than Adefovir for Long-Term Treatment of Resistant Hepatitis B Virus: Presented at AASLD

        By Crystal Phend

        SAN FRANCISCO, CA -- November 23, 2005 -- Tenofovir (Viread) appears to be more effective and less affected by resistance mutations than adefovir for long term use in patients with lamivudine resistant hepatitis B, researchers said here at the American Association for the Study of Liver Diseases' (AASLD) annual meeting.

        Tenofovir gives "fast and stable suppression of HBV DNA" compared to adefovir, said lead author Florian van Bömmel, MD, Physician, Department of Hepatology and Gastroenterology, Charité Campus Virchow Klinikum, Berlin, Germany.

        Adefovir dipivoxil (Hepsera) is a nucleotide analogue that treats lamivudine resistant hepatitis B virus. Tenofovir is a nucleotide analogue that is approved for treatment of HIV and is also active against hepatitis B virus.

        Recent research results showed the two drugs have different virological responsiveness after 1 year of therapy. In their study, Dr. van Bömmel and colleagues extended the comparison to almost 3 years for virological and immunological effectiveness and mutations in the hepatitis B virus polymerase gene.

        In a presentation on November 14th Dr. van Bömmel presented the retrospective study, which included 88 patients with lamivudine resistant hepatitis B who then received either tenofovir or adefovir.

        One group of 35 patients switched directly to tenofovir at a dose of 300 mg and followed for 33 months. The 53 patients that switched to adefovir received 10 mg and were followed for an average of 4 months.

        The two treatment groups had no significant differences in virus genotype, virus DNA levels at baseline, viral resistance at baseline or percentage of patients co-infected with HIV.

        Patients were monitored for elevated liver enzymes and virus DNA once every 3 months.

        At 12 months, 94% of patients on tenofovir had undetectable virus levels compared with 32% on adefovir. By 18 months, all of the tenofovir patients had undetectable levels compared with 35% of adefovir patients. At 24 months, tenofovir was still at 100% while adefovir reached 49% at undetectable levels.

        No significant adverse effects were noted in either group and liver enzyme levels remained in normal ranges.

        Variations in virus DNA levels according to mutations were not present in the tenofovir group but mutations did significantly lower suppression rates in the adefovir group at months 12 and 18.

        The researchers concluded that tenofovir is superior to adefovir in this setting.

        "Monotherapy with adefovir is not recommended," Dr. van Bömmel said.


        [Presentation title: Long-Term Effect of Tenofovir in the Treatment of Lamivudine-Resistant Hepatitis B Virus Infections in Comparison to Adefovir. Abstract 184]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send